



Contents lists available at ScienceDirect

Chinese Chemical Letters

journal homepage: [www.elsevier.com/locate/cclet](http://www.elsevier.com/locate/cclet)

Original article

## A facile method for building fused quinoxaline-quinolinones *via* an acidless post-Ugi cascade reaction

Yong Li<sup>a,b</sup>, Jie Lei<sup>a,b</sup>, Jia Xu<sup>a,b</sup>, Dian-Yong Tang<sup>b</sup>, Zhong-Zhu Chen<sup>b,\*</sup>, Jin Zhu<sup>a,b</sup>, Chuan Xu<sup>c,\*</sup><sup>a</sup> Key Laboratory for Asymmetric Synthesis and Chiral Technology of Sichuan Province Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, Chengdu 610041, China<sup>b</sup> Chongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, China<sup>c</sup> Department of Oncology, Chengdu Military General Hospital, Chengdu 610083, China

## ARTICLE INFO

## Article history:

Received 8 August 2016

Received in revised form 11 October 2016

Accepted 14 October 2016

Available online xxx

## Keywords:

Quinoxaline

Quinolono[3,4-*b*]quinoxalin-6(5*H*)-one

Ugi/deprotection/cyclization (UDC) strategy

Nucleophilic substitution reaction

One-pot

## ABSTRACT

A series of quinolino[3,4-*b*]quinoxalin-6(5*H*)-ones have been synthesized using an Ugi/deprotection/cyclization (UDC) strategy, followed by a nucleophilic aromatic substitution reaction. This facile microwave-assisted method provided good yields and could potentially be used for the construction of a diverse library of quinolino[3,4-*b*]quinoxalin-6(5*H*)-ones for high-throughput screening in medicinal chemistry.

© 2016 Zhong-Zhu Chen and Chuan Xu. Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.

### 1. Introduction

Nitrogen-containing heterocycles are important compounds that can be found in a wide range of drugs and biologically relevant molecules [1]. For this reason, research towards the development of novel and efficient strategies for the construction of these compounds represents one of the most active areas of present day synthetic organic chemistry [2]. Multicomponent reactions (MCRs) have become useful tools for the diversity-oriented synthesis of complex heterocyclic compounds [3]. One of the powerful multicomponent reactions is the Ugi reaction, which involves the effective multicomponent reaction of an aldehyde (or ketone), amine, isonitrile and carboxylic acid to afford an  $\alpha$ -acylamino carboxamide adduct [4,5]. Tandem reaction sequences involving the use of an Ugi reaction, followed by various post-condensation transformations, represent extremely powerful synthetic methods for the construction of heterocyclic compounds with elaborate substitution patterns [6]. For example, Ugi/Buchwald–Hartwig/Michael [7], Ugi/Heck [8], Ugi/Aldo [9], Ugi/Bischler Napieralski

[10] and Ugi/gold-catalyzed [11] reaction sequences have been reported to provide efficient access to a wide variety of cyclic scaffolds.

The quinoxaline skeleton is found in a wide range of biologically active natural products (1,2,5, Fig. 1) and synthetic compounds (3, 4, Fig. 1) [12]. Notably, quinoxaline derivatives have been reported to display a wide range of biological properties, including anticancer [13], antitumor (*i.e.*, thymidylate synthase inhibitors) [14], antibacterial [15], antifungal [16], antihypertensive [17] and dopamine agonist [18] activities. In this study, we used a UDC, followed by an intermolecular nucleophilic substitution reaction to prepare a series of novel quinolino[3,4-*b*]quinoxalin-6(5*H*)-one compounds. It is noteworthy, however, these compounds were formed unexpectedly during our efforts to prepare a related scaffold and therefore represent a serendipitous discovery.

The synthesis of a series of fused piperazine-benzimidazoles *via* an UDC strategy was reported [19]. It was envisaged that we could expand the scope of this research to the construction of much more interesting and structurally complex compounds with a wide range of biological activities. During the last decade, G-quadruplexes have emerged as valid targets for the development of new anticancer drugs [20]. Numerous compounds have been reported to target these structures, and some of these compounds progressed into preclinical or clinical trials for the treatment of

\* Corresponding authors.

E-mail addresses: [18883138277@163.com](mailto:18883138277@163.com) (Z.-Z. Chen), [1535486239@qq.com](mailto:1535486239@qq.com) (C. Xu).<http://dx.doi.org/10.1016/j.ccllet.2016.10.027>

1001–8417/© 2016 Zhong-Zhu Chen and Chuan Xu. Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.




Fig. 1. Quinoxaline natural and prepared products.


53 cancer. It is noteworthy that most of the compounds designed  
54 against G-quadruplexes are based on polycyclic heteroaromatic  
55 scaffolds, which could be constructed from Ugi products following  
56 a series of nucleophilic substitution reactions to provide access to  
57 additional aromatic ring structures. It was therefore envisioned  
58 that the reaction of 2-oxo-2-phenylacetaldehyde **6a** with isonitrile  
59 **7a**, *N*-Boc-protected-phenylenediamine **8a** and *N*-Boc amino acetic  
60 acid **9** under the tandem UDC conditions would provide access to  
61 the corresponding benzo[4,5]imidazo[1,2-*a*]pyrazine derivative  
62 **14**, as shown in Scheme 1.

## 63 2. Results and discussion

64 The Ugi product **10a** was obtained in good yield and subjected  
65 to a Boc-deprotection step to afford intermediate **11a**. It was  
66 anticipated that compound **11a** would react as indicated by the  
67 arrows shown in Scheme 1 to give compound **12**. This material  
68 would then undergo a dehydrogenation reaction to give interme-  
69 diate **13**, followed by a nucleophilic aromatic substitution reaction

70 to provide the target compound **14** in the presence of an inorganic  
71 base catalyst, such as Cs<sub>2</sub>CO<sub>3</sub> or Na<sub>2</sub>CO<sub>3</sub>. In practice, however, the  
72 UDC product resulting from the reaction of **11a** was determined to  
73 be the quinoxaline derivative **15a** instead of the expected product  
74 **12**. Notably, the formation of **15a** involved the cleavage of the  
75 amino acid group from **11a** during the UDC strategy when the  
76 cyclization was conducted under acidic condition. To develop a  
77 detailed understanding and further expand the scope of this  
78 process, we investigated the application of these reaction  
79 conditions to a series of different starting materials (Scheme 2).  
80 The results of these reactions revealed that they gave rise to the  
81 corresponding quinoxaline products.

82 The Ugi product **10** was obtained following the reaction of the  
83 *N*-Boc amino acetic acid **9** with *N*-Boc-protected-phenylenedi-  
84 amine **8**, 2-oxo-2-phenylacetaldehyde **6** and isonitrile **7** in  
85 methanol at room temperature overnight, and used in the next  
86 reaction without purification. The methanol solvent was removed  
87 under a gentle stream of nitrogen to give a residue, which was  
88 dissolved in 10% TFA/DCE and heated under microwave irradiation  
89



Scheme 1. Ugi/deprotection/cyclization (UDC) strategy.

Download English Version:

<https://daneshyari.com/en/article/5142866>

Download Persian Version:

<https://daneshyari.com/article/5142866>

[Daneshyari.com](https://daneshyari.com)